Growth Hormone Deficiencies/Abnormalities Clinical Trials

This study is for children that has growth hormone deficiency (GHD), testing a weekly injection.

This is a Phase IV, multicenter, open-label, single-arm study of somatropin (rDNA origin) (Nutropin AQ v1.1) in pre-pubertal children with growth hormone deficiency (GHD) naive to prior recombinant human growth hormone (rhGH) treatment. The study is designed to characterize the immunogenicity profile of Nutropin AQ v1.1 when administered as a ...

Subjects with MLIV are seen annually for 5 years to assess ongoing for physical and neurological changes associated with the disease.

A multicenter, phase 3, long-term extension trial of TransCon hGH administered once-weekly in children with growth hormone deficiency (GHD) who previously participated in a phase 3 TransCon hGH trial. Approximately 400 children (males and females) with GHD will be included. All study participants will receive TransCon hGH. This is a ...

Subjects for this study will be recruited if they are: Adults, male or female aged 18 years or older Have been diagnosed with pituitary diseases

The purpose of this study is to evaluate the long-term safety and effectiveness of growth hormone (Eutropin Inj./Eutropin plus Inj.) treatment with GHD (Growth Hormone Deficiency), TS (Turner Syndrome),CRF (Chronic Renal Failure), SGA (Small for Gestational Age), and ISS (Idiopathic Short Stature).

Protocol Summary: The hypotheses are: growth hormone (GH) deficiency in children with chromosome 18 deletions is accompanied by cognitive and microstructural abnormalities of the brain that can be ameliorated by GH treatment; and the physical and behavioral findings in individuals with abnormalities of chromosome 18 are due to the genes ...